Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Various monoclonal antibodies (mAb) target immune system molecules to enhance immunity by costimulating T cells (i.e., CD137, OX40, CD40, GITR) or interfering in coinhibitory signals (i.e., CTLA-4, PD-1). These powerful agents can be guided by cancer vaccines to enhance immunity against tumor but not self tissues. Clinically powerful therapeutic synergies are at hand.

Original publication

DOI

10.1158/1078-0432.ccr-08-2931

Type

Journal article

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

03/2009

Volume

15

Pages

1507 - 1509

Addresses

Gene Therapy Unit, Centro de Investigación Médica Aplicada (CIMA), Clinica Universitaria, Universidad de Navarra, Pamplona, Spain. imelero@unav.es

Keywords

T-Lymphocytes, Animals, Humans, Neoplasms, Neoplasm Proteins, Cancer Vaccines, Antibodies, Monoclonal, Drug Combinations, Lymphocyte Activation, Immunity